The role of anti-proliferative effects of atorvastatin on uterine fibroids: findings from a clinical study.

Ghafarzadeh, Masoumeh; Shakarami, Amir; Yari, Fatemeh; Marzban Rad, Zahra

Uterine myomas/fibroids are one of the most common benign tumors of the reproductive system in women. Given pleiotropic effects of statins, the aim of this study is to evaluate the therapeutic effects of atorvastatin on uterine fibroids in women of reproductive age. This randomized clinical study included 90 women aged 35–45 years with uterine fibroids. The patients were randomly allocated into the intervention group (received one tablet, 20 mg of atorvastatin every day for three months) and placebo. Ultrasound was performed every month, and the change in the size of fibroids was recorded for each patient. At the end of the study, the data obtained were analyzed using SPSSv22 and a p value 3 vs 35.16 ± 6.67 mm3) p =.0001. However, the decrease in fibroid size from 1st month to the 3rd month was not statistically significant, p =.189 (36.71 ± 5.54 mm3 vs 35.16 ± 6.67 mm3). This study shows that treatment with atorvastatin might positively reduce the size of fibroids. The decrease was only statistically significant during the first month. Further studies with a detailed analysis of the intervention's clinical impact are required to consider statins as a therapeutic tool.

UTERINE fibroids; ATORVASTATIN; CHILDBEARING age; GENITALIA; ULTRASONIC imaging; UTERINE hemorrhage; BENIGN tumors

Gynecological Endocrinology, 2021, Vol 37, Issue 8, p721

0951-3590

Academic Journal

10.1080/09513590.2021.1922884